US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Strong cash flow despite the influence of Covid-19

FIRST QUARTER 2020 (JAN - MAR)· Total net sales (incl. durable goods) in the quarter amounted to SEK 46.5 (47.7) million, corresponding to a decrease of 3 percent in SEK and 6 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 44.2 (46.8) million, corresponding to a decrease of 6 percent in SEK and 9 percent in local currency. · Sales from warm perfusion represented 27 percent (43) of sales of non-durable goods. Sales of warm perfusion products were affected in March partly due to fewer EVLP:s being performed and partly because some orders were not

A historic year ended with a quarter of sales records

FOURTH QUARTER 2019 (OCT - DEC) ·  Net sales of non-durable goods in the quarter amounted to SEK 59.4 (52.3) million, corresponding to an increase of 14 percent in SEK and 6 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 62.4 (58.4) million, corresponding to an increase of 7 percent in SEK and 0 percent in local currency. · Net sales of non-durable goods in the quarter amounted to SEK 59.4 (52.3) million, corresponding to an increase of 14 percent in SEK and 6 percent in local currency. Total net sales (incl. durable goods) in the

Third XPS™ sold in Australia

The Fiona Stanley Hospital in Perth, Western Australia has recently acquired an XPS from XVIVO Perfusion AB (publ). This acquisition now sees three of the four Australian hospitals participating in the adult heart and lung transplant program having access to an XPS to assist in performing EVLP (Ex Vivo Lung Perfusion).  The Fiona Stanley Hospital XPS was kindly donated by Conquer Cystic Fibrosis Inc and the Spinnaker Health Research Foundation.XVIVO Perfusion has sold an XPS to Fiona Stanley Hospital in Perth, Western Australia. Together with The Prince Charles Hospital, Brisbane and The

XVIVO opens a subsidiary in Australia

Based on the increasing interest for XVIVO Perfusion´s products for lung transplantation as well as the high interest from all Australian clinics to participate in the Heart preservation study XVIVO Perfusion AB (publ) has decided to open a subsidiary in Sydney, Australia.   XVIVO also recently hired a Regional Business Manager with start date in October 2019.Currently XVIVO has two XPS-systems installed in the Pacific region and during the year the company noted an increasing interest from all five Lung transplant clinics to purchase an XPS. During the summer all heart transplant clinics

XVIVO Perfusion AB (publ) issue of warrants of series 2019/2021 fully subscribed

The annual general meeting in XVIVO Perfusion AB (publ) (”XVIVO”) on 25 April 2019 resolved to issue up to 351,000 share warrants of series 2019/2021 to employees of XVIVO and XVIVO’s Swedish subsidiaries, with a date of employment on or before 18 October 2019. A total of 351 000 warrants were subscribed which means that the issue has been subscribed in full.Each warrant entitles to subscribe for one new share in XVIVO for a subscription price corresponding to 150 percent of the volume weighted average price for XVIVO´s shares quoted on Nasdaq Stockholm for each trading day during (i) the

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January - September 2019. The presentation will be held in English.Time: Thursday, October 24, 2019 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:https://event.on24.com/wcc/r/2099777/BE7D608FBDE20DDC5E0315BE8A97C986 or shortly before time of the conference starts on:Sweden dial in number: +46 (0) 8 5664 2651 USA dial in number: +1 631 913 1422 International dial in number: +44 (0) 3333 000 804Conference name: XVIVO Perfusion,

Perfadex® Plus has received patent approval in Europe

XVIVO Perfusion has received European patent approval for the company’s ready to use product Perfadex® Plus for cold preservation of lungs. Perfadex® Plus was launched in Europe and the US in 2018.As XVIVO Perfusion has previously reported, the company has developed a new ready to use version of its product for cold preservation of lungs. Patent applications for the new formulation, which is called Perfadex® Plus, have been submitted in all important markets and the European patent authority has now approved the patent in Europe. Perfadex® Plus was launched in the principal markets, the US

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report January - June 2019. The presentation will be held in English.Time: Friday, July 12, 2019 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:http://event.on24.com/wcc/r/2032218-1/6B026E6E35CA4FDF60624857784BF612 or shortly before time of the conference starts on:Sweden dial in number: +46 (0) 8 5664 2651USA dial in number: +1 631 913 1422International dial in number: +44 (0) 3333 000 804 Conference name: XVIVO Perfusion, conference

Report from Annual general meeting of XVIVO Perfusion AB (publ)

The following resolutions were amongst those adopted at XVIVO Perfusion’s Annual General Meeting held on April 25, 2019: • No dividend will be paid for the financial year 2018. • Gösta Johannesson, Camilla Öberg, Folke Nilsson, Yvonne Mårtensson and Alan Raffensperger were re-elected as members of the Board, and Dag Andersson was elected as new member of the Board and Gösta Johannesson was elected Chairman of the Board, all in accordance with the proposal of the Election Committee. • Remuneration totaling SEK 1,180,000 shall be paid to members of the Board: SEK 250,000 to the

STRONG GROWTH IN WARM PERFUSION AND PROGRESS IN THE R&D PORTFOLIO

FIRST QUARTER 2019 (JAN - MAR)· Net sales of non-durable goods in the quarter amounted to SEK 46.8 (37.9) million, corresponding to an increase of 24 percent in SEK and 13 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 47.7 (42.5) million, corresponding to an increase of 12 percent in SEK and 3 percent in local currency.   · Sales from warm perfusion represented 43 percent (35) of sales of non-durable goods. · Operating income before depreciation and amortization (EBITDA) adjusted for costs for a share-based bonus program for employees

XVIVO Perfusion AB (publ) Report on operations 2018

THE YEAR ENDED WITH CONTINUED STRONG GROWTH AND GOOD EBITDAFOURTH QUARTER 2018 (OCT - DEC) · Total net sales in the quarter amounted to SEK 58.4 (41.6) million, corresponding to an increase of 40 percent in SEK and 33 percent in local currency. Net sales of non-durable goods* in the quarter amounted to SEK 52.3 (39.4) million, corresponding to an increase of 33 percent in SEK and 26 percent in local currency. · Warm perfusion sales of non-durable goods** showed a record growth of more than 50 percent during the quarter. Sales from warm perfusion represented 50 percent (43) of sales

XVIVO Perfusion AB (publ) Interim Report January – September 2018

GOOD SALES GROWTH DRIVEN BY WARM PERFUSIONTHIRD QUARTER 2018 (JUL - SEP) • Total net sales in the quarter amounted to SEK 40.9 (32.3) million, corresponding to an increase of 27 percent. The increase corresponds to 18 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 40.3 (31.6) million, corresponding to an increase of 27 percent in SEK. Sales of non-durable goods increased by 18 percent in local currency.• Sales from warm perfusion* showed a growth record of more than 60 percent during the quarter. Sales from warm perfusion represented 40 percent

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the Interim report January – September 2018. The presentation will be held in English.Time: Friday, October 26, 2018 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link:http://event.on24.com/wcc/r/1851559-1/25B7D535D0DF7E99165C1B13785FB88F  or shortly before time of the conference starts on: Sweden dial in number: +46 (0)8 5664 2651 USA dial in number: +1 631 913 1422International dial in number: +44 (0)3333 0008 04Conference name: XVIVO Perfusion,

Nomination Committee of XVIVO Perfusion AB (publ)

The following members have been appointed to XVIVO Perfusion’s Nomination Committee for the 2019 Annual General Meeting: Henrik Blomquist, representing Bure Equity ABJoachim Spetz, representing Swedbank RoburMartin Lewin, representing Eccenovo ABGösta Johannesson, Chairman of the Board The appointments have been made in accordance with the instructions regarding principles for the appointment of the company Nomination Committee which were determined at the Annual General Meeting of XVIVO Perfusion AB (publ) on April 27, 2018. The members of the Nomination Committee together

Interim report January-June 2018

GOOD SALES GROWTH AND IMPORTANT MILESTONES PASSEDSECOND QUARTER 2018 (APRIL-JUNE) · Total net sales in the quarter amounted to SEK 46.1 (37.0) million, corresponding to an increase of 24 percent. The increase corresponds to 23 percent in local currency. Net sales of non-durable goods in the quarter amounted to SEK 42.2 (36.4) million, corresponding to an increase of 16 percent in SEK. Sales of non-durable goods increased by 14 percent in local currency · Operating income before depreciation and amortization (EBITDA) amounted to SEK 8.1 (5.7) million, corresponding to an EBITDA

Perfadex Plus approved by the FDA

XVIVO Perfusion has received marketing approval (510k) in the United States from the FDA for the company's 'ready-to-use' product Perfadex Plus for cold preservation of lungs. It is already launched in European countries and will be launched in August on the important US market. About 40 percent of all lung transplants are performed in the United States.As XVIVO Perfusion has reported earlier, the company has developed a new, ready-to-use version of its cold preservation product for lungs. Patent applications have been submitted for the new formulation called Perfadex Plus. It is currently

XVIVO Perfusion launches Perfadex Plus, an upgraded ready to use version of Perfadex

XVIVO Perfusion has spent nearly five years developing a ready to use version of its´ product for cold preservation of lungs. The new upgraded version of Perfadex is named Perfadex Plus and the company has filed for patent for Perfadex Plus. It is currently being launched in European countries and is expected to be available in all major markets within 12 months.Perfadex is the market gold standard and has been marketed by XVIVO Perfusion since 1999. It is used for cold preservation of lungs i.e. flushing away donor blood and preserving the donated lungs before transplantation. It is being

There are no items matching the current filter
There are no more items matching the current filter
Back to top